Understand the source comparison
SS-LUP-332 Comparison — Clearance and Half-Life Profiles
SS-LUP-332 ~72 hours 10–14 days Hepatic CYP3A4, renal excretion 92–95% (albumin, 1-AGP) Extended half-life requires 3–4 week washouts in sequential protocols; high protein binding creates reservoir effect GW501516 (Cardarine) 16–24 hours 5–7 days Hepatic oxid
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SS-LUP-332
- ~72 hours
- 10–14 days
- Hepatic CYP3A4, renal excretion
- 92–95% (albumin, α1-AGP)
- Extended half-life requires 3–4 week washouts in sequential protocols; high protein binding creates reservoir effect
- GW501516 (Cardarine)
- 16–24 hours
- 5–7 days
- Hepatic oxidation, renal
- 78–82%
- Faster clearance than SS-LUP-332 but similar PPAR mechanism; often used as comparator in metabolic studies
- Rosiglitazone
- 3–4 hours
- 24–36 hours
- Hepatic CYP2C8
- 99.8%
- Short half-life but extremely high protein binding; full clearance faster despite binding saturation
- Fenofibrate
- 20 hours
- 4–6 days
- Hydrolysis to fenofibric acid, renal
- 99%
- PPARα-selective; shorter persistence than SS-LUP-332 but similar washout caution for combination studies
- Pioglitazone
- 3–7 hours (parent), 16–24 hours (active metabolites)
- 7–10 days
- Hepatic CYP2C8/3A4
- Metabolite persistence extends detectable window despite short parent half-life
- SS-LUP-332's 72-hour half-life is the longest among commonly used PPAR modulators in research, which has implications for both chronic dosing schedules and endpoint timing. Most fenofibrate or rosiglitazone studies can use 7–10 day washouts; SS-LUP-332 requires nearly double that to achieve equivalent clearance confidence.